IPdR: a novel oral radiosensitizer.

Abstract

IPdR (5-iodo-2-pyrimidinone-2'-deoxyribose) is a novel orally available, halogenated thymidine (TdR) analog and is a potential radiosensitizer for use in human tumors, such as rectal, pancreas, sarcoma and glioma tumors. IPdR is a prodrug that is efficiently converted to IUdR (5-iodo-2'-deoxyuridine), an intravenous radiosensitizer by a hepatic aldehyde oxidase, resulting in high IPdR and IUdR plasma levels in mice for > or = 1 h after oral IPdR. Athymic mice tolerated oral IPdR to doses up to 1500 mg/kg/day t.i.d. for 6 - 14 days without significant systemic toxicities. A number of in vivo preclinical studies have demonstrated that IPdR is a superior radiosensitizer compared with IUdR given as a continuous infusion in terms of safety and efficacy with a significantly lower toxicity profile, including gastrointestinal and hematologic side effects. A preclinical study has shown that IPdR is effective in inducing human colon cancer xenograft radiosensitization in drug-resistant DNA mismatch repair-proficient and -deficient tumor models, as well as in human globlastoma xenograft. In anticipation of performing a clinical Phase I trial in humans, investigators also studied the drug pharmacokinetics and host toxicities in two non-rodent, animal species during a 14-day treatment course. Dose-limiting systemic toxicities (diarrhea, emesis, weight loss and decreased motor activity) were observed in ferrets receiving IPdR at 1500 mg/kg/day on a 14-day schedule that were not found previously in athymic mice. Recently, a once-daily IPdR dosing up to 2000/mg/kg for 28 days in Fischer-344 rats showed reversible mild-to-moderate systemic toxicities without any severe or life-threatening toxicities. However, in all preclinical toxicity studies so far, no significant hematologic, biochemical or histopathologic changes have been found. Hepatic aldehyde oxidase activity was reduced in a dose-dependent fashion in the ferret liver, suggesting partial enzyme inactivation by this IPdwR schedule, but that is not found in Fischer-344 rats. The plasma pharmacokinetic profile in Rhesus monkeys showing biexponential clearance are similar to previously published data in athymic mice. In this paper, the authors review the development, mechanism of action, preclinical data and rationale for clinical studies.

• Authors: Muhammad Wasif Saif, Greg Berk, Yung-Chi Cheng, Timothy James Kinsella
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 16 Issue 9 Pg. 1415-24 (Sep 2007) ISSN: 1744-7658 [Electronic] England
• PMID: 17714027 (Publication Type: Journal Article, Review)

Chemical References

• Drugs, Investigational
• Pyrimidine Nucleosides
• Radiation-Sensitizing Agents
• ropidoxuridine

Topics

• Animals
• Cell Line, Tumor
• Drug Evaluation, Preclinical (methods)
• Drugs, Investigational (administration & dosage, pharmacokinetics)
• Humans
• Pyrimidine Nucleosides (administration & dosage, pharmacokinetics)
• Radiation-Sensitizing Agents (administration & dosage, pharmacokinetics)
• Xenograft Model Antitumor Assays (methods)